Effects of FEIBA on platelet and leucocyte activation in severe haemophilia patients with inhibitors

References

• Carcao M, Lambert T. Prophylaxis in haemophilia with inhibitors: Update from international experience. Haemophilia 2010; 16: 16–23
   PubMed Web of Science ®Google Scholar
• Negrier C, Goudemand J, Sultan Y, Bertrand M, Rothschild C, Lauroua P. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity. Thromb Haemost 1997; 77: 1113–1119
   PubMed Web of Science ®Google Scholar
• Dimichele D, NÉGrier C. A retrospective postlicensure survey of FEIBA efficacy and safety. Haemophilia 2006; 12: 352–362
   PubMed Web of Science ®Google Scholar
• Astermark J, Donfield SM, DiMichele DM, Gringeri A, Gilbert SA, Waters J, Berntorp E, FENOC Study Group. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: The FEIBA NovoSeven Comparative (FENOC) Study. Blood 2007; 109: 546–551
   PubMed Web of Science ®Google Scholar
• Rangarajan S, Yee TT, Wilde J. Experience of four UK comprehensive care centres using FEIBA® for surgeries in patients with inhibitors. Haemophilia 2010; 17: 28–34
   Web of Science ®Google Scholar
• Penner JA. Management of haemophilia in patients with high-titre inhibitors: Focus on the evolution of activated prothrombin complex concentrate AUTOPLEX® T. Haemophilia 1999; 5: 1–9
   PubMed Web of Science ®Google Scholar
• Berntorp E. Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors. Haemophilia 2009; 15: 3–10
   PubMed Web of Science ®Google Scholar
• Gallistl S, Cvirn G, Leschnik B, Muntean W. Respective roles of factors II, VII, IX, and X in the procoagulant activity of FEIBA. Blood Coagul Fibrin 2002; 13: 653–655
   PubMed Web of Science ®Google Scholar
• Ehrlich HJ, Henzl MJ, Gomperts ED. Safety of factor VIII inhibitor bypass activity (FEIBA®): 10-year compilation of thrombotic adverse events. Haemophilia 2002; 8: 83–90
   PubMed Web of Science ®Google Scholar
• Aledort LM. Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. J Thromb Haemost 2004; 2: 1700–1708
   PubMed Web of Science ®Google Scholar
• Vergnolle N, Derian CK, D’Andrea MR, Steinhoff M, Andrade-Gordon P. Characterization of thrombin-induced leukocyte rolling and adherence: A potential proinflammatory role for proteinase-activated receptor-4. J Immunol 2002; 169: 1467–1473
   PubMed Web of Science ®Google Scholar
• Váradi K, Negrier C, Berntorp E, Astermark J, Bordet J-C, Morfini M, Linari S, Schwarz HP, Turecek PL. Monitoring the bioavailability of FEIBA with a thrombin generation assay. J Thromb Haemost 2003; 1: 2374–2380
   PubMed Web of Science ®Google Scholar
• Konstantopoulos K, Neelamegham S, Burns AR, Hentzen E, Kansas GS, Snapp KR, Berg EL, Hellums JD, Smith CW, McIntire LV, et al. Venous levels of shear support neutrophil-platelet adhesion and neutrophil aggregation in blood via P-Selectin and ß2-integrin. Circulation 1998; 98: 873–882
   PubMed Web of Science ®Google Scholar
• Evangelista V, Manarini S, Sideri R, Rotondo S, Martelli N, Piccoli A, Totani L, Piccardoni P, Vestweber D, de Gaetano G. Platelet/polymorphonuclear leukocyte interaction: P-selectin triggers protein-tyrosine phosphorylation-dependent CD11b/CD18 adhesion: Role of PSGL-1 as a signaling molecule. Blood 1999; 93: 876–885
   PubMed Web of Science ®Google Scholar
• Zhao L, Bath P, Heptinstall S. Effects of combining three different antiplatelet agents on platelets and leukocytes in whole blood in vitro. Br J Pharmacol 2001; 134: 353–358
   PubMed Web of Science ®Google Scholar
• Dargaud Y, Lienhart A, Negrier C. Prospective assessment of thrombin generation test for dose monitoring of bypassing therapy in hemophilia patients with inhibitors undergoing elective surgery. Blood 2010; 16: 5734–5737
   Google Scholar
• Camera M, Frigerio M, Toschi V, Brambilla M, Rossi F, Cottell DC, Maderna P, Parolari A, Bonzi R, De Vincenti O, et al. Platelet activation induces cell-surface immunoreactive tissue factor expression, which is modulated differently by antiplatelet drugs. Arterioscler Thromb Vasc Biol 2003; 23: 1690–1696
   PubMed Web of Science ®Google Scholar
• McEver RP, Cummings RD. Perspectives series: Cell adhesion in vascular biology. Role of PSGL-1 binding to selectins in leukocyte recruitment. J Clin Invest 1997; 100: 485–491
   PubMed Web of Science ®Google Scholar
• Hankey GJ, Eikelboom JW. Dabigatran etexilate: A new oral thrombin inhibitor. Circulation 2011; 123: 1436–1450
   PubMed Web of Science ®Google Scholar